O6-Methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent- based chemotherapy

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 807-814

  Silber, John R ^a,d   Blank, A ^b   Bobola, Michael S ^a,c   Ghatan, Saadi ^a   Kolstoe, Douglas D ^a   Berger, Mitchel S ^a,e  

^a Box 356470 ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CISPLATIN; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TIOGUANINE; VINCRISTINE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TREATMENT OUTCOME; ADOLESCENT; AGED; BRAIN; BRAIN TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYMOLOGY; GLIOMA; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHENOTYPE; TREATMENT OUTCOME;

EID: 0032588748     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Berger, M. S., Spence, A. M., and Stelzer, K. J. Brain tumors. In: M. C. Brain and P. P. Carbone (eds.), Current Therapy in Hematology/ Oncology. Philadelphia, PA: Mosby Publishers, pp. 525-542, 1995.
2. Prados, M. D., and Russo, C. Chemotherapy for brain tumors. Semin. Surg. Oncol., 14: 88-95, 1998.
3. Beranek, D. T. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res., 231: 11-30, 1990.
4. Ludlum, D. B. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Invest., 15: 588-598, 1997.
5. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol., 51: 167-223, 1995.
6. 6-methylguanine-DNA methyltransferase to monofunctional alkylating agent resistance in human brain tumor-derived cell lines. Mol. Carcinog., 13: 70-80, 1995.
7. 6-methylguanine-DNA methyltransferase to resistance to 1,3-bis-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines. Mol. Carcinog., 13: 81-88, 1995.
8. 6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin. Cancer Res., 2: 735-741, 1996.
9. Friedman, H. S., Dolan, M. E., Pegg, A. E., Marcelli, S., Keir, S., Catino, J. J., Bigner, D. D., and Schold, S. C. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res., 55: 2853-2857, 1995.
10. 6-benzyl-2′-deoxyguanosine and BCNU. Cancer Res., 56: 2076-2081, 1996.
11. 6-alkyltransferase activity in human brain and brain tumors. Carcinogenesis (Lond.), 5: 121-124, 1984.
12. 6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung and ovary. Cancer Res., 51: 4131-4134, 1991.
13. 6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis (Lond.), 7: 745-749, 1986.
14. 6-alkylguanine-DNA alkyltransferase activity in human brain tumors. Cancer Lett., 55: 153-158, 1990.
15. 6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res., 53: 3416-3420, 1993.
16. 6-methylguanine-DNA methyltransferase in human brain tumors detected by activity assay and monoclonal antibodies. Oncol. Res., 7: 49-55, 1995.
17. Belanich, M., Pastor, M., Randall, T. Guerra, D., Kibitel, J., Alas, L., Li, B., Citron, M., Wasserman, P., White, A., Eyre, H., Jaeckle, K., Schulman, S., Rector, D., Prados, M., Coons, S., Shapiro, W., and Yarosh, D. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res., 56: 783-788, 1996.
18. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res., 58: 1068-1073, 1998.
19. 6-benzylguanine and its role in chemotherapy. Clin. Cancer Res., 6: 837-847, 1997.
20. 6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Proc. Natl. Acad. Sci. USA, 93: 6941-6946, 1996.
21. 6-methylguanine-DNA methyltransferase. Oncol. Res., 5: 83-86, 1993.
22. 6-alkylguanine-DNA alkyltransferase activity in human cells and tumor tissues by restriction endonuclease inhibition. Cancer Res., 47: 6229-6235, 1987.
23. 6-methylguanine-DNA methyltransferase. Cancer Res., 51: 3339-3344, 1991.
24. Bland, M. An Introduction to Medical Statistics. New York, NY: Oxford University Press, 1995.
25. Preston-Martin, S. Epidemiology of primary CNS neoplasms. Neuroepidemiology, 14: 273-290, 1996.
26. 4-methylthymine DNA repair methyltransferase gene. EMBO J., 10: 2179-2186, 1991.
27. 6-methylguanine DNA repair methyltransferase. J. Bacteriol., 173: 2068-2076, 1991.
28. Walker, K. A., Jennings, C. D., Pulliam, J., Ogburn, C., Martin, G. M., Urano, M., and Turker, M. S. A cell line selected for resistance to ionizing radiation exhibits cross resistance to other genotoxic agents and a mutator phenotype for loss of heterozygosity events. Somat. Cell Mol. Genet., 23: 111-121, 1997.
29. Yount, G. L., Haas-Kogan, D. A., Levine, K. S., Aldape, K. D., and Israel, M. A. Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: implications for combined modality therapy. Cancer Res., 58: 3819-3825, 1998.
30. 6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy. Carcinogenesis (Lond.), 17: 637-641, 1996.
31. 6-methylguanine-DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell Biol., 17: 5612-5619, 1997.
32. Issa, J-P. J., and Baylin, S. B. Epigenetics and human disease. Nat Med., 2: 281-282, 1996.
33. 6-benzylguanine plus BCNU. Cancer Res., 57: 4817-4823, 1997.
34. Engleward, B. P., Dreslin, A., Christensen, J., Huzar, D., Kurachara, C., and Samson, L. Repair-deficient 3-methyladenine glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J., 15: 945-952, 1996.